[89Zr]Zr-DFO-sacituzumab govitecan

A **radiolabeled antibody-drug conjugate** consisting of **sacituzumab govitecan** (a humanized anti-Trop-2 monoclonal antibody conjugated via a hydrolyzable linker to SN-38, the active metabolite of irinotecan) that is further chelated with the radioisotope zirconium-89 ([89Zr]) using DFO (desferrioxamine) as a chelator. This construct enables specific noninvasive PET imaging of Trop2-expressing tumors, allowing for biodistribution, target engagement, and potentially therapy response monitoring in patients treated with sacituzumab govitecan. The immunoPET agent is typically under investigation for use in solid tumors, especially **triple-negative breast cancer (TNBC)**, for assessing Trop-2 expression and monitoring disease[3][9].

Other names

[89Zr]Zr-DFO-sacituzumab govitecan[89Zr]Zr-DFO-Trodelvy